Did you know?
ChinaBio® Group is an investment, consulting and media firm helping western life science companies achieve success in China. ChinaBio works with U.S., European and APAC companies seeking partnerships, acquisitions, novel technologies and funding in China.  

>> Learn more…

Site Search

>> Advanced Search

  Quick Search:
 
 

Free Newsletter

  Email address:
   

Beijing Leadman Biochemistry Completes ChiNext IPO

publication date: Feb 16, 2012
View a Printer Friendly version of this page, allowing you to print the page. Send a summary of this page to someone via email.
Beijing Leadman Biochemistry completed an IPO on the Shenzhen’s ChiNext exchange, raising almost 500 million RMB ($79 million). The company issued 38.4 million shares at a price of 13 RMB. Leadman produces IVD reagents, medical devices, and chemical raw materials. The issue price reflects a PE ratio of 37. In its first open market session, Leadman rose even higher, climbing 25% to 16.2 RMB per share. More details....

Stock Sumbol: (SHE: 300289)

Share this with colleagues:  


This article is available for purchase - please click here for details.


Sorry... this feature or article is only available to subscribers.

>> Learn more about our subscription plans...

>> Free email newsletter...

>> Login...

Login

  

    
   
Alibaba IPO
Event Updates
Greg Scott will be attending and speaking at these events:
 
 
 
Hope to see you there!
 
ChinaBio® Events
ChinaBio Leadership Retreat 2014
Suzhou, China
October 23-24, 2014
 
China Forum 2014

Frankfurt, Germany
November 2, 2014

>> More events...

Our Partners
Annual Sponsors
Official Partners
Supporting Partners
Media Sponsors